Hims & Hers won’t sell compounded version of Novo’s obesity pill
Hims & Hers announced on Saturday that it would discontinue the sale of a compounded version of Novo Nordisk’s obesity pill on its telehealth platform. This decision came after concerns were raised about the legality of the company’s actions by health officials.
The controversy began earlier in the week when Hims launched the compounded drug at a significantly lower price of $49 per month. This move was met with immediate backlash from Novo Nordisk, the pharmaceutical company behind the original pill, which had priced its oral version of the injectable Wegovy treatment at $149 to $299 per month just a month prior. Under normal circumstances, the mass production of generic copies of a brand-name drug is only permitted in cases where the drug is facing a shortage.
The situation escalated when the Food and Drug Administration (FDA) announced that it would take action against companies like Hims that were marketing unapproved, compounded versions of GLP-1 drugs. Then, on Friday, the Department of Health and Human Services (HHS) requested the Department of Justice to investigate Hims for potential violations of federal law.
The dispute between Hims and Novo Nordisk underscores the complexities of the pharmaceutical industry and the importance of adhering to regulatory guidelines. It also raises questions about the role of telehealth platforms in providing access to medications and the implications of offering lower-cost alternatives to brand-name drugs.
As the investigation into Hims continues, it remains to be seen how this will impact the company’s telehealth offerings and its relationship with pharmaceutical manufacturers. Stay tuned for updates on this developing story.
